Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.58% | 18.06% | 4.19% | 5.43% | 17.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.58% | 18.06% | 4.19% | 5.43% | 17.48% |
| Cost of Revenue | 47.99% | 15.80% | 0.11% | 2.35% | -25.14% |
| Gross Profit | 5.51% | 18.19% | 4.43% | 5.67% | 21.01% |
| SG&A Expenses | 60.32% | 60.42% | 63.69% | 66.47% | 66.36% |
| Depreciation & Amortization | 0.00% | 0.06% | -0.06% | -13.18% | 83.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.74% | 49.26% | 50.27% | 60.62% | 21.20% |
| Operating Income | -292.58% | -184.40% | -279.49% | -344.27% | -44.90% |
| Income Before Tax | -484.92% | -354.68% | -532.47% | -701.20% | -291.15% |
| Income Tax Expenses | 6,610.09% | -530.87% | -669.54% | -1,420.08% | -314.48% |
| Earnings from Continuing Operations | -2,774.33% | -324.23% | -502.19% | -611.38% | -104.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,774.33% | -324.23% | -502.19% | -611.38% | -104.67% |
| EBIT | -292.58% | -184.40% | -279.49% | -344.27% | -44.90% |
| EBITDA | -361.08% | -223.60% | -346.14% | -456.91% | -39.93% |
| EPS Basic | -2,737.29% | -318.16% | -494.33% | -601.81% | -101.92% |
| Normalized Basic EPS | -192.95% | -348.21% | -524.32% | -690.10% | -27.29% |
| EPS Diluted | -2,554.44% | -318.16% | -476.50% | -601.81% | -80.00% |
| Normalized Diluted EPS | -192.95% | -348.21% | -524.32% | -690.10% | -27.29% |
| Average Basic Shares Outstanding | 1.36% | 1.42% | 1.33% | 1.33% | 1.35% |
| Average Diluted Shares Outstanding | 1.36% | 1.42% | 1.33% | 1.33% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |